Piramal Critical Care Docks For China Push

Peter DeYoung, CEO of Piramal Critical Care, tells Scrip about his plans to take the group’s inhalation anesthesia portfolio to China and talks of the greater “competitive intensity” in the US amid quicker ANDA approvals by the FDA. Timelines around the potential US launch of the inhaled anesthetic agent, desflurane, however, appear hazy.

Peter De'Young
PIRAMAL CRITICAL CARE CEO PETER DEYOUNG

Piramal Critical Care, the world's third-largest producer of inhaled anesthetics and part of Piramal Enterprises Ltd., appears to be gearing up for an assault on the Chinese market.

Registration plans for its inhalation anesthesia products are underway and alliances are part of the efforts to tap into the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip